Diatos S.A. Completes a Series D €9.4 Million Private Financing Round

PARIS--(BUSINESS WIRE)--Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, has announced the successful closing of a financing round raising €9.4 million. The round was led by existing investors of Diatos including GIMV (Belgium), Credit Agricole Private Equity (France), InterWest Partners (United States), Innoven Partenaires (France), Sofinnova Partners (France) and Biotech Fund Flanders (Belgium), also participated in the round additional existing investors including AGF Private Equity (France), NIF SMBC (Japan), Sopartec (Belgium), and SGAM (France). This brings the total equity capital raised by Diatos since its inception in 1999 to date to €54.8 million.

MORE ON THIS TOPIC